Supplemental Figure 1 from Breast Cancer Polygenic-Risk Score Influence on Risk-Reducing Endocrine Therapy Use: Genetic Risk Estimate (GENRE) Trial 1-Year and 2-Year Follow-Up

Supplemental Figure 1: The Study Schema Defines Information Collected During Each Patient Visit and at Each Follow-Up Time Point. Visit 1 consisted of a baseline breast cancer risk assessment (NCI-BCRAT and IBIS BC risk scores without PRS) and discussion of risk-reducing options, including ET, with a participating physician or nurse practitioner. During Visit 2, NCI-BCRAT and IBIS BC risk scores, with and without PRS, were presented and explained to participants, and ET risks, benefits, and potential adverse effects were discussed again. ET prescriptions were provided to those who wished to proceed. The participants completed the same survey as was completed after Visit 1. Follow-up assessments were performed 1 and 2 years after Visit 2 and evaluated QOL with the FACT-GP/ES questionnaire.